Market Research Report: Biocon Limited

Company Overview

Name, Mission of the Company

Name: Biocon Limited

Mission: To be an integrated biotechnology enterprise of global distinction with excellence in intellectual asset creation through discovery, research and development, state-of-the-art manufacturing capabilities, internationally benchmarked quality and regulatory systems, new medical insights through disease-specific clinical research, customer relationship through outstanding products and services, human resource development through training, mentoring and empowering, and management of research and business partnerships.

Founding Details

Founded: 29-Nov-1978

Founders: Kiran Mazumdar-Shaw and Biocon Biochemicals Ltd. Ireland

Key People

Executive Chairperson: Kiran Mazumdar-Shaw

CEO & Managing Director: Siddharth Mittal

CEO & Managing Director, Biocon Biologics: Shreehas P. Tambe

Group CEO: Peter Bains

CEO & Managing Director, Syngene International: Jonathan Hunt

Headquarters

Location: Bengaluru, Karnataka, India

Number of Employees

Total Employees: 16,300+

Revenue

Revenue (FY24): ₹15,621 Crore

Recognition and Expertise

Biocon is known for path-breaking work in the fields of generics, biosimilars, novel biologics, and research services. The company is a pioneer in biotechnology in India and has leveraged India's value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed, and quality.

Products

Generics

Portfolio: Atorvastatin, Aminocaproic Acid, Dapagliflozin, Dasatinib, Dorzolamide, Esomeprazole, Everolimus, Fingolimod, Labetalol, Lenalidomide, Liothyronine, Mycophenolic Acid, Mycophenolic Sodium, Pemetrexed, Posaconazole, Pravastatin, Rosuvastatin, Simvastatin, Tacrolimus, Teriflunomide, Vigabatrin.

Biosimilars

Insulins

Products: Insulin Glargine (Basalog, Basalog One, Glaricom, Glarzia, Semglee, and more), Rh-insulin (Insugen, Recomulin).

Other Biosimilars

Trastuzumab: Ogivri, Zedora, Canmab, Hertraz, Canhera, HerzmAb, BisintEX, MabTIn, Tuzepta, Priunta, Trastuget.

Pegfilgrastim: Fulphila.

Bevacizumab: Krabeva, Abevmy.

Novel Biologics

Nimotuzumab (BIOMAb-EGFR®): For head & neck cancer.

Itolizumab (ALZUMAb™): For Psoriasis.

Research Services

Managed by Syngene, Biocon offers drug discovery, development, and manufacturing services tailored to client needs.

Key Features of Products

Generics: Cost-effective treatment options that cover a wide range of therapeutic areas.

Biosimilars: High-quality, affordable alternatives to expensive biologic medications.

Novel Biologics: Innovative therapies for oncology and immunology that transform treatment standards.

Recent Developments

New Product Launches

Sacubitril/Valsartan Tablets: Approved by the US FDA, used for treating chronic heart failure in adults and pediatric patients over the age of one year.

Daptomycin for Injection: Approved by the US FDA, indicated for complicated skin and skin structure infections and Staphylococcus aureus infections in the bloodstream.

New Partnerships and Approvals

Partnership with Sandoz: Collaboration for the sale of biosimilar Trastuzumab and Bevacizumab in Australia.

Partnership with Eris Lifesciences: Expand patient access to Biocon Biologics' Metabolics, Oncology, and Critical Care products in India.

Approval of Biosimilar Aflibercept: US FDA approval enabling entry into the US Ophthalmology market.

Regulatory Milestones

US FDA Approvals: Sacubitril/Valsartan Tablets, Daptomycin Injection, approval for antifungal drug Micafungin, and tacrolimus capsules from SAHPRA.

EMA Approvals: New monoclonal antibodies facility in India, renewals of GMP certifications for sites in India and Malaysia.

First US FDA-approved interchangeable biosimilar: Semglee (Insulin Glargine).

Conclusion

This detailed report aims to present a comprehensive overview of Biocon Limited by synthesizing data related to its overview, product portfolio, and recent developments, delivering an information-dense analysis designed for professional use.